Biotech hedge fund launches new immunology company for atopic dermatitis

A biotech hedge fund is creating a new company to develop a long-acting antibody treatment for atopic dermatitis, signaling increased private investment in immunology. The move reflects a trend of financial investors directly building biotech startups rather than funding existing ones. The specific target and clinical timeline remain undisclosed.